Antithrombotic Potential of Pentoxifylline A Hemorheologically Active Drug

Angiology

Volumn 36, Issue 6, 1985, Pages 387-398

  Schröer, Reiner H ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; INDOMETACIN; PENTOXIFYLLINE;

ANIMAL EXPERIMENT; CHEEK POUCH; DRUG THERAPY; FIBRINOLYSIS; HAMSTER; HAMSTER CHEEK POUCH; MOUTH; NONHUMAN; PERIPHERAL VASCULAR SYSTEM; PRIORITY JOURNAL; THERAPY;

ANIMAL; ASPIRIN; BLOOD COAGULATION; EPOPROSTENOL; FIBRINOLYSIS; HAMSTERS; HAPLORHINI; HEMOSTASIS; HUMAN; PENTOXIFYLLINE; PLATELET AGGREGATION; RATS; THEOBROMINE; THROMBOEMBOLISM; THROMBOSIS;

EID: 0021798170     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/000331978503600608     Document Type: Article

References (76)

1. Harlan JM, Harker LA: Hemostasis, thrombosis and thromboembolic disorders. Med Clin North Am 65: 855, 1981.
2. Meyer D., Baumgartner HR: Role of von Willebrand factor in platelet adhesion to the subendothelium. Br J Haematol 54: 1, 1983.
3. Holmsen H.: Platelet secretion. In: Hemostasis and Thrombosis, basic principles and clinical practice. Ed. by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia, Toronto, JB Lippincott Co, 1982, p. 390.
4. Zwaal Rfa, Hemker HC: Blood cell membranes and haemostasis. Haemostasis 11: 12, 1982.
5. Van Rijn Jlm, et al: The interaction between blood platelets and blood coagulation factors. Arzneim-Forsch/Drug Res 33(II): 1365, 1983.
6. Walsh PN, Griffin JH: Contributions of human platelets to the proteolytic activation of blood coagulation factors XII and XI. Blood 57: 106, 1981.
7. Baumgartner HR, Muggli R.: Adhesion and aggregation: Morphological demonstration and quantitation in vivo and in vitro. In: Platelets in Biology and Pathology. Ed. by Gordon JL. New York, Elsevier, 1976, p. 23.
8. Davie EW, Hanaham DJ: Blood coagulation proteins. In: The plasma proteins, Vol. 3. Ed. by Putnam F. New York, Academic Press, 1975, p. 421.
9. Baumgartner HR, Kuhn H.: Thrombosis ex vivo: the rate of obstruction in annular flow chambers increase with the blood shear rate. Thrombos Haemost 50: 168, 1983.
10. Baumgartner HR: The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 5: 167, 1973.
11. Schmid-Schönbein H., et al: A counter-rotating rheoscope chamber for the study of the microrheology of blood cell aggregation by microscopic observation and microphotometry. Microvasc Res 6: 366, 1973.
12. Turitto VT, Baumgartner HR: Platelet-surface interactions. In: Hemostasis and thrombosis, basic principles and clinical practice. Ed. by Colman RW, Hirsh J, Marder VJ, Salzmann EW. Philadelphia, Toronto, JB Lippincott Co, 1982, p. 364.
13. Moncada S., Vane JR: Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30: 293, 1978.
14. Vanhoutte PM, Cohen RA, Van Nueten JM: Serotonin and arterial vessels. J Cardiovasc Pharmacol 6: S421, 1984.
15. Nakazawa K., Murata K.: Acidic glycosaminoglycans in three layers of human aorta: Their different constitution and anticoagulant function. Arterial Wall 2: 203, 1975.
16. Cooper DR, et al: ADP metabolism in vascular tissue, a possible thromboregulatory mechanism. Thromb Res 14: 901, 1979.
17. Czervionke RL, Hoak JC, Fry GL: Effect of aspirin on thrombin-induced adherence of platelets to cultured cells from the blood vessel wall. J Clin Invest 63: 1089, 1979.
18. Boeynaems JM, Galand N.: Stimulation of vascular prostacyclin synthesis by extracellular ADP and ATP. Biochem Biophys Res Commun 112: 290, 1983.
19. Lollar P., Owen WG: Clearance of thrombin from circulation in rabbits by high affinity binding sites on endothelium. J Clin Invest 66: 1222, 1980.
20. Esmon CT, Owen WG: Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 78: 2249, 1981.
21. Comp PC, Esmon CT: Activated protein C inhibits platelet prothrombin converting activity. Blood 54: 1272, 1979.
22. Heymann E., Mentlein R.: A negative blood-clotting factor lining the vessels. Naturwissenschaften 69: 189, 1982.
23. Collen D.: On the regulation and control of fibrinolysis. Thromb Haemost 43: 77, 1980.
24. Comp PC, Esmon CT: Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 68: 1221, 1981.
25. Thompson AR, Harker LA: Clinical approach to thrombosis and thromboembolism. In: Manual of hemostasis and thrombosis, Edition 3. Ed. by Thompson AR, Harker LA. Philadelphia, FA Davis Co, 1983, p. 131.
26. Stemerman MB: Relationship of thrombosis to atherosclerosis. In: Hemostasis and thrombosis, basic principles and clinical practice. Ed. by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia, Toronto, JB Lippincott Co, 1982, p. 781.
27. Sinzinger H., Feigl W., Silberbauer K.: Prostacyclin generation in atherosclerotic arteries. Lancet 2: 442, 1979.
28. Muller-Mohnssen H., Kratzer M., Baldauf W.: Microthrombus formation in models of coronary arteries caused by stagnation point flow arising at the predilection sites of atherosclerosis and thrombosis. In: The role of fluid mechanics in atherogenesis. Proceedings from a specialists meeting, Ohio, Aug 24-25, 1978, p. 12.1.
29. Goldsmith HL, Karino T.: Platelets in a region of disturbed flow. Trans Am Soc Artif Intern Organs 23: 632, 1977.
30. Thomas DP: Pathogenesis of venous thrombosis. In: Haemostasis and thrombosis. Ed. by Bloom AL, Thomas DP. Edinburgh, London, Melbourne, New York, Churchill Livingstone, 1981, p. 637.
31. Hirsh J.: Hypercoagulability. Semin Hematol 14: 409, 1977.
32. Stewart GJ: The role of hypercoagulability in thrombosis. Br J Haematol 40: 359, 1978.
33. Satewachin II, et al: The use of pentoxifylline in a combined regimen for the prevention of re-thrombosis in major blood vessels. Pharmatherapeutica 2(Suppl. 1): 109, 1978.
34. Itoh T., Satoh T.: Influence of pentoxifylline (Trental) on platelet aggregation and serum lipids in patients with obstructive cerebrovascular disorders. Pharmatherapeutica 2: 159, 1979.
35. Brevetti G., et al: La pentossifillina nel trattamento delle arteriopatie obliteranti al secondo stadio. Prog Med Roma 35: 363, 1979.
36. Takamatsu S., et al: A two year follow-up study on blood constituents in aged arteriosclerotic patients treated with pentoxifylline. In: Pathophysiology and pharmacotherapy of cerebrovascular disorders. Ed. by Betz E, Grote J. Heuser D, Wüllenweber R. Baden-Baden, Köln, New York, Verlag G Witzstrock, 1980, p. 290.
37. Angelkort B., Kiesewetter H.: Influence of risk factors and coagulation phenomena on the fluidity of blood in chronic arterial occlusive disease. Scand J Clin Lab Invest 41(Suppl. 156): 185, 1981.
38. Perego MA, Sergio G., Artale F.: Haemorheological aspects of the pathophysiology and clinical features of peripheral occlusive arterial disease. Pharmatherapeutica 3(Suppl. 1): 91, 1983.
39. Muggeo M., et al: Blood clotting, fibrinolytic and haemorheological parameters in ischaemic vascular disease: the effects of pentoxifylline in the treatment of acute cerebral vascular disease. Pharmatherapeutica 3(Suppl. 1): 74, 1983.
40. Ott E., Lechner H.: Changes of flow properties of the blood in cerebrovascular disease and their medical treatment with pentoxifylline. J Cerebr Blood Flow Metab 3(Suppl. 1): 530, 1983.
41. Di Perri T., et al: Studies of the clinical pharmacology and therapeutic efficacy of pentoxifylline in peripheral obstructive arterial disease. Angiology 35: 427, 1984.
42. Strano A., et al: Clinical evaluation of the effects of pentoxifylline in patients with chronic peripheral circulatory disorders. Pharmatherapeutica 3(Suppl. 1): 117, 1983.
43. Strano A., et al: Double-blind crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35: 459, 1984.
44. Matzky R., Darius H., Schrör K.: The release of prostacyclin (PGI2) by pentoxifylline from human vascualr tissue. Arzneim-Forsch/Drug Res 32: 1315, 1982.
45. Weithmann KU: Reduced platelet aggregation by pentoxifylline-stimulated prostacyclin release. VASA 10: 249, 1981.
46. Kuzuya F.: Influence of pentoxifylline (Trental) on platelet aggregation. Gendai No Shinryo 19: 1567, 1977.
47. Moncada S., et al: An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263: 663, 1976.
48. Sinzinger H.: Pentoxifylline enhances formation of prostacyclin from rat vascular and renal tissue. Prostagl Leukotr Med 12: 217, 1983.
49. Schrör K: unpublished results.
50. Pohanka E., Sinzinger H.: Effect of a single pentoxifylline administration on platelet sensitivity, plasma factor activity and plasma 6-oxo-PGF1α and thromboxane B2 in healthy volunteers. Submitted for publication, 1984.
51. Sinzinger H., et al: Decreased sensitivity of human platelets to PGI2 during longterm intraarterial prostacyclin infusion in patients with peripheral vascular disease - a rebound phenomenon? Prostaglandins 21: 49, 1981.
52. Kostka-Trabka E., et al: Pentoxifylline (Trental) in treatment of arteriosclerosis obliterans. Zbl Pharm 122: 763, 1983.
53. Kaser-Glanzmann R., et al: Stimulation of calcium uptake in platelet membrane vesicles by adenosine 3'5'cyclic monophosphate and protein kinase. Biochem Biophys Acta 466: 429, 1977.
54. Detwiler TC, Charo IF, Feinman RD: Evidence that calcium regulates platelet function. Thromb Haemost 40: 207, 1978.
55. Ambrus JL, et al: Study of platelet aggregation in vivo I. Effect of Bencyclan. J Med 7: 439, 1976.
56. Gastpar H., et al: Study of platelet aggregation in vivo III. Effect of pentoxifylline. J Med 8: 191, 1977.
57. Ambrus JL, Ambrus CM, Gastpar H.: The role of platelet aggregation in metastatic dissemination and thrombo-embolic complications in cancer patients. Prevention with pentoxifylline. In: Disorders of blood flow-New therapeutic aspects. Ed. by Manrique RV, Müller R. Amsterdam, Oxford, Princeton, Excerpta Medica, 1981, p. 29.
58. Jarret Pem, Moreland M., Browse NL: The effect of pentoxifylline (Trental) on fibrinolytic activity and plasma fibrinogen levels. Curr Med Res Opin 4: 492, 1977.
59. Dembinska-Kiec A., Kostka-Trabka E., Gryglewski RJ: Effect of prostacyclin on fibrinolytic activity in patients with arteriosclerosis obliterans. Thrombos Haemostas 47: 190, 1982.
60. Robbins KC: The plasminogen-plasmin enzyme system. In: Hemostasis and thrombosis, basic principles and clinical practice. Ed. by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia, Toronto, JB Lippincott Co, 1982, p. 623.
61. Begent N., Born Gvr: Growth rate in vivo of platelet thrombi, produced by iontophoresis of ADP, as a function of mean blood flow velocity. Nature 227: 926, 1970.
62. Michal M., Giessinger N.: The effect of pentoxifylline on thrombus formation in vivo. Abstr No 565, 9th Int Congr Pharmacol, July 29-Aug 3, London, 1984.
63. Arfors KE, et al: Biolaser endothelial trauma as a means of quantifying platelet activity in vivo. Nature 217: 887, 1968.
64. Philp RB, Francey J., Warren BA: Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. Haemostasis 7: 282, 1978.
65. Weichert W., Pauliks V., Breddin HK: Laser-induced thrombi in rat mesenteric vessels and antithrombotic drugs. Haemostasis 13: 61, 1983.
66. Weichert W., Breddin HK: Antithrombotic effects of acetylsalicylic acid (ASA) and pentoxifylline in a model of laser-induced thrombosis in rats. Submitted for publication, 1984.
67. Seiffge D.: Dependence of laser-induced thrombus formation and embolisation on blood flow velocity. Int J Microcirc Clin Exp 3: 423, Abstr 304, 1984.
68. Pietsch K., et al: Neue Befunde zur Wirkung von Acetylsalicylsäure: Die Hemmwirkung auf den Formwandel der Thrombozyten und ihre Bedeutung fur die Dosierung als Antithrombotikum. In: Diabetische Angiopathien. Ed. by Alexander K, Cachovan M. Baden-Baden, Brüssel, Köln, New York, Verlag G Witzstrock, 1977, p. 348.
69. Weichert W., Breddin HK: Effects of antibiotics on laser-induced thrombus formation in rat mesenteric arterioles. Haemostasis 1985, submitted for publication.
70. Cazenave JP, et al: Effects of cephalothin and penicillin G on platelet function in vitro. Brit J Haemat 35: 135, 1977.
71. Fields WS, et al: Controlled trial of aspirin in cerebral ischemia. Stroke 8: 302, 1977.
72. Lewis HD, et al: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. New Engl J Med 309: 396, 1980.
73. Müller R.: On the therapy of disturbances of blood fluidity. Angiology 36: 226, 1985.
74. Koppenhagen K.: Personal communications. 1980.
75. Herskovits E., et al: Randomized trial of pentoxifylline versus acetylsalicylc acid plus dipyridamole in preventing transient ischemic attacks. Lancet I: 966, 1981.
76. Lucas MA: Prevention of post-operative thrombosis in peripheral arteriopathies. Pentoxifylline vs. conventional antiaggregants: A six-month randomized follow-up study. Angiology 35: 443, 1984.